EP Patent

EP4454654A2 — Treatment of amyotrophic lateral sclerosis (als)

Assigned to Voyager Therapeutics Inc · Expires 2024-10-30 · 2y expired

What this patent protects

The present disclosure relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and delivery methods for the treatment of spinal cord related disorders including ALS.

USPTO Abstract

The present disclosure relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and delivery methods for the treatment of spinal cord related disorders including ALS.

Drugs covered by this patent

Patent Metadata

Patent number
EP4454654A2
Jurisdiction
EP
Classification
—
Expires
2024-10-30
Drug substance claim
No
Drug product claim
No
Assignee
Voyager Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.